Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Insider Sells 277 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 277 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $11,332.07. Following the transaction, the insider now owns 111,984 shares of the company’s stock, valued at $4,581,265.44. This represents a 0.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Dennis Cho also recently made the following trade(s):

• On Monday, February 3rd, Dennis Cho sold 806 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total value of $39,776.10.
• On Friday, January 3rd, Dennis Cho sold 144 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total value of $6,564.96.
• On Friday, December 20th, Dennis Cho sold 316 shares of Twist Bioscience stock. The stock was sold at an average price of $44.90, for a total value of $14,188.40.
• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The stock was sold at an average price of $46.81, for a total value of $6,225.73.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $36.71 on Tuesday. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of -10.86 and a beta of 2.15. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The stock has a fifty day moving average of $46.54 and a 200 day moving average of $45.47. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.75) earnings per share. On average, research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Institutional Trading of Twist Bioscience

Several large investors have recently modified their holdings of TWST. Wilmington Savings Fund Society FSB bought a new stake in Twist Bioscience during the 3rd quarter valued at approximately $34,000. Van ECK Associates Corp boosted its position in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares in the last quarter. Banque Transatlantique SA bought a new stake in shares of Twist Bioscience in the 4th quarter worth approximately $43,000. GF Fund Management CO. LTD. bought a new stake in shares of Twist Bioscience in the 4th quarter worth approximately $58,000. Finally, US Bancorp DE raised its holdings in Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after acquiring an additional 601 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on TWST shares. TD Cowen restated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Wolfe Research started coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Barclays set a $58.00 price objective on Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, Robert W. Baird boosted their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.